- Home
- IMMR vs KPTI Comparison
IMMR vs KPTI Comparison
Compare IMMR & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMMR | KPTI |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.5M | 194.8M |
| IPO Year | 1999 | 2013 |
Fundamental Metrics
Financial Performance| Metric | IMMR | KPTI |
|---|---|---|
| Price | $6.48 | $9.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $13.50 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 465.8K | 448.8K |
| Earning Date | 04-13-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | $35,013,000.00 | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | $345.50 | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $5.25 | $3.65 |
| 52 Week High | $8.15 | $10.99 |
Technical Indicators
Market Signals| Indicator | IMMR | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 51.98 |
| Support Level | $6.33 | $5.43 |
| Resistance Level | $6.88 | $9.58 |
| Average True Range (ATR) | 0.23 | 0.89 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 44.84 | 57.69 |
Price Performance
Historical ComparisonAbout IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).